Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

BCBA/GSK stock hub

BCBA/GSK has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/GSKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

139.6T

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/GSK

In the news

Latest news · BCBA/GSK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9.9

P25 n/aP50 n/aP75 n/a

Trailing P/E13.1

P25 n/aP50 n/aP75 n/a

ROE40.9

P25 n/aP50 n/aP75 n/a

ROIC26.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/GSK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

224

Groups with data

Currency

GBP

Showing 224 of 224 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	AR
Employees	66,841
Employees Change	-1,583%
Employees Change Percent	-2.25
Enterprise value	ARS 168.5T
Exchange	Buenos Aires Stock Exchange
Financial currency	GBP
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	ARS 139.6T
Price	ARS 18,740
Price currency	ARS
Rev Per Employee	894,644,265.15x
Sic	2834
Symbol	bcba/GSK
Website	https://www.gsk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.62%
EV Earnings	15.85x
EV/EBIT	8.97x
EV/EBITDA	7.63x
EV/FCF	14.49x
EV/Sales	2.71x
FCF yield	8.33%
Forward P/E	9.86x
P/B ratio	4.39x
P/E ratio	13.13x
P/S ratio	2.33x
PE Ratio10 Y	90.22x
PE Ratio3 Y	14.7x
PE Ratio5 Y	13.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	30.22%
EBITDA Margin	34.88%
FCF margin	19.45%
Gross margin	72.87%
Gross Profit	ARS 43.6T
Gross Profit Growth	5.34%
Gross Profit Growth Q	2.97%
Gross Profit Growth3 Y	5.29%
Gross Profit Growth5 Y	3.18%
Net Income	ARS 10.6T
Net Income Growth	84.87%
Net Income Growth Q	6.96%
Net Income Growth3 Y	-26.44%
Net Income Growth5 Y	2.09%
Pretax Margin	22.69%
Profit Margin	17.78%
Profit Per Employee	ARS 159.1M
ROA	10.02
Roa5y	7.23
ROCE	24.49
ROE	40.91
Roe5y	32.1
ROIC	26.7
Roic5y	22.54

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	79%
Cagr3y	68.81%
Cagr5y	61.41%
Div CAGR10	47.7%
Div CAGR3	122.45%
Div CAGR5	118.15%
EPS Growth	86.56
EPS Growth Q	8.4
EPS Growth3 Y	-26.53
EPS Growth5 Y	1.74
FCF Growth	18.47%
FCF Growth Q	-1.81%
FCF Growth3 Y	19.56%
FCF Growth5 Y	-0.62%
OCF Growth	14.78%
OCF Growth Q	-0.35%
OCF Growth10 Y	11.09%
OCF Growth3 Y	16.34%
OCF Growth5 Y	-0.18%
Revenue Growth	3.97x
Revenue Growth Q	1.5x
Revenue Growth3 Y	4.07x
Revenue Growth5 Y	1.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.53
Assets	ARS 114.7T
Cash	ARS 6.3T
Current Assets	ARS 33.9T
Current Liabilities	ARS 42.8T
Debt	ARS 34.9T
Debt EBITDA	ARS 1.64
Debt Equity	ARS 1.1
Debt FCF	ARS 3
Equity	ARS 31.8T
Interest Coverage	14.94
Liabilities	ARS 82.9T
Long Term Assets	ARS 80.8T
Long Term Liabilities	ARS 40.1T
Net Cash	ARS -28.6T
Net Cash By Market Cap	ARS -20.47
Net Debt EBITDA	ARS 1.37
Net Debt Equity	ARS 0.9
Net Debt FCF	ARS 2.46
Tangible Book Value	ARS -13.8T
Tangible Book Value Per Share	ARS -3,437

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.79
Inventory Turnover	1.46
Net Working Capital	ARS -5.6T
Quick ratio	0.51
Working Capital	ARS -8.5T
Working Capital Turnover	ARS -16,131

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.13%
Dividend Growth	59.29%
Dividend Growth Years	4%
Dividend per share	ARS 535
Dividend Years	5
Dividend Yield	2.86%
Ex Div Date	2026-02-20
Last Dividend	ARS 166
Payout Frequency	Quarterly
Payout Ratio	44.52%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	78.93%
200-day SMA	17,584.3
3Y total return	381.18%
50-day SMA	20,314.4
50-day SMA vs 200-day SMA	50over200
5Y total return	995.37%
All Time High	22,760
All Time High Change	-17.66%
All Time High Date	2026-02-18
All Time Low	543.1
All Time Low Change	3,350.4%
All Time Low Date	2019-07-05
ATR	407.5
Ch YTD	0.27
High	18,780
High52	22,760
High52 Date	2026-02-18
High52ch	-17.66%
Low	18,620
Low52	10,400
Low52 Date	2025-05-13
Low52ch	80.19%
Ma50ch	-7.75%
Price vs 200-day SMA	6.57%
RSI	33.51
RSI Monthly	65.75
RSI Weekly	48.93
Sharpe ratio	1.58x
Sortino ratio	2.62
Total Return	3.98%
Tr YTD	1.05
Tr1m	-9.77%
Tr1w	-1.73%
Tr3m	-15.8%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS 18.1T
Operating Income Growth	59.89
Operating Income Growth Q	19.83
Operating Income Growth3 Y	10.08
Operating Income Growth5 Y	6.55
Operating margin	30.22

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,864,337,078%
Net Borrowing	1,016,319,620,022.2
Shares Insiders	0.07%
Shares Institutions	86.82%
Shares Qo Q	-0.29%
Shares Yo Y	-1.13%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 10.9T
Average Volume	496.45x
Bv Per Share	8,101.1
CAPEX	ARS -2.5T
Ch1m	-9.77
Ch1w	-1.73
Ch1y	72.72
Ch3m	-16.45
Ch3y	342.5
Ch5y	889.6
Ch6m	9.53
Change	-0.21%
Change From Open	-0.21
Close	18,780
Days Gap	0
Depreciation Amortization	2,913,576,696,799.2
Dollar Volume	6,352,860
Earnings Date	2026-04-29
EBIT	ARS 18.1T
EBITDA	ARS 20.9T
EPS	ARS 2,591
F Score	7
FCF	ARS 11.6T
FCF EV Yield	6.9x
Financing CF	-7,791,372,053,134
Fiscal Year End	December
Founded	1,715
Goodwill	13,894,786,249,722.6
Graham Number	11704.38999
Graham Upside	-37.54
Income Tax	ARS 2T
Investing CF	-8,309,459,073,291
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Date	2022-07-22
Last Split Type	Reverse
Lynch Fair Value	ARS 7,136
Lynch Upside	-61.92
Ma150	19,010
Ma150ch	-1.42%
Ma20	20,232
Ma20ch	-7.37%
Net CF	-1,997,553,827,718
Next Earnings Date	2026-07-29
Open	18,780
P FCF Ratio	12
P OCF Ratio	9.89
Payment Date	2026-04-09
Position In Range	75
Ppne	19,140,368,378,580.4
Price Date	2026-05-08
Price EBITDA	ARS 6.69
Relative Volume	0.68x
Revenue	59,798,917,326,561x
SBC By Revenue	1.14x
Share Based Comp	682,269,526,545
Tax By Revenue	3.3x
Tax Rate	14.54%
Tr6m	11.22%
Volume	339
Z Score	2.09

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BCBA/GSK dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+2.9%

$535 annual per share

Payout ratio

+44.5%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+118.2%

4 consecutive years of growth

Total shareholder yield

+4.0%

Next ex-dividend date: 2026-02-20

Performance

BCBA/GSK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/GSK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+86.8%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-1.1%

Negative means the company is buying back shares.

Technical

BCBA/GSK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

33.5

Neutral momentum band

Price vs 200-day MA

+6.6%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.58

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/GSK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/GSK stock rating?

bcba/GSK is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/GSK analysis?

The full report lives at /stocks/bcba/GSK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/GSK?

The latest report frames bcba/GSK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/GSK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.